Bridge Laboratories to build second facility in Beijing
US-owned, preclinical contract research organisation Bridge Laboratories has reached an agreement to build its second preclinical facility in China.
US-owned, preclinical contract research organisation Bridge Laboratories has reached an agreement to build its second preclinical facility in China.
The purpose-built, 150,000ft2 facility will be adjacent to Bridge's existing laboratory in the Zhongguancun Life Science Park in Beijing. Construction of the new laboratory will begin in the fourth quarter of 2008, with completion expected in late fourth quarter 2009.
Designed to meet US FDA and worldwide regulatory standards, it will provide GLP toxicology, immunology, vaccine, and bioanalytical services. The new facility will quadruple Bridge's available laboratory space in Beijing.
"China is becoming a very attractive solution to many multinational pharmaceutical and biotech companies," said Tom Oakley, president and ceo, Bridge Laboratories. "We have an established presence and are prepared to meet the growing requirements for preclinical services.
"We are looking forward to using this new facility to expand our relationships with our current customers and to build relationships with new customers who are looking for high-quality, lower cost alternatives for their preclinical development needs."